# Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/VOR/vor-bio-to-participate-in-the-2026-jefferies-global-healthcare-conference-045fc6d4
Ticker: VOR
Company: Vor Biopharma
Source: Vor Biopharma
Published: 2026-05-28 12:30 EST
## Summary

Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases,...

## Article Body
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.

Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET

A live webcast of the presentation may be accessed on the Investors section of the Vor website at ir.vorbio.com. A replay of the webcast will be available on the Vor website for approximately 30 days following the presentation.

About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com .
## Recent Company News
- 2026-07-07 20:01 EST — [Vor Bio Appoints David Zaccardelli to Board of Directors](https://biopharmsignal.com/news/VOR/vor-bio-appoints-david-zaccardelli-to-board-of-directors-7c744ed5) — Source: Vor Biopharma
- 2026-07-02 21:30 EST — [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ef99a3b3) — Source: Vor Biopharma
- 2026-06-08 12:31 EST — [Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China](https://biopharmsignal.com/news/VOR/telitacicept-receives-nmpa-approval-for-the-treatment-of-sj-gren-s-disease-in-ch-185b18e7) — Source: Vor Biopharma
- 2026-06-08 12:30 EST — [Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China](https://biopharmsignal.com/news/VOR/telitacicept-receives-nmpa-conditional-approval-for-the-treatment-of-iga-nephrop-59acfea5) — Source: Vor Biopharma
- 2026-06-01 21:00 EST — [Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/VOR/vor-bio-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-955d407c) — Source: Vor Biopharma
## Related News
- 2026-07-28 20:15 EST — BDX — [BD Board Declares Dividend](https://biopharmsignal.com/news/BDX/bd-board-declares-dividend-ea66eb4a)
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)